Anthera Pharmaceuticals to price $83.75 million public sale of stock

Canaccord is lead co-manager; bookrunners Citi, Leerink Swann assist

By Devika Patel

Knoxville, Tenn., June 2 - Anthera Pharmaceuticals, Inc. will price a public sale of its common stock, according to a prospectus supplement filed Thursday with the Securities and Exchange Commission.

Citi and Leerink Swann are the joint bookrunning managers and Canaccord Genuity is the lead co-manager.

Proceeds will be used for general corporate purposes.

Anthera, based in Hayward, Calif., is a biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.